A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder

NCT00892125 | Completed Phase 1

• 1 other identifier: CR011440
• Study Type: interventional
• Target: 64
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purposes of this study are to evaluate the effects of a potent metabolic enzyme inducer, carbamazepine, on the steady-state pharmacokinetics of orally administered paliperidone ER and to evaluate the safety and tolerability of the treatments in clinically stable patients with a diagnosis of schizophrenia or bipolar I disorder.

Conditions

Schizophrenia; Bipolar Disorder

Keywords

Schizophrenia; Bipolar I disorder; mood disorders; antipsychotic drugs; enzyme inducer; Paliperidone ER

Outcome Measures

Primary Outcomes (1)

• to evaluate the effects of a potent enzyme inducer, carbamazepine, on the steady-state pharmacokinetics of orally administered paliperidone ER

Secondary Outcomes (1)

• to evaluate the safety and tolerability of the treatments in clinically stable patients with a diagnosis of schizophrenia or bipolar I disorder

Interventions

paliperidone ER; Carbamazepine DRUG

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Diagnosis of schizophrenia of any subtype (295.10
• ) or bipolar I disorder (296.0x, 296.4x, 296.5x, 296.6x or 296.7), according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
• Clinically stable with no psychiatric hospitalization or change in existing mood stabilizers, antipsychotic, or anti-manic drugs for 3 months before screening. A reduction in the dose of existing medication is acceptable if the subject remained clinically stable throughout the 3 month period. In addition, an increase or decrease in the dose of a mood stabilizer on the basis of therapeutic drug monitoring or the substitution of a specific mood stabilizer, antipsychotic, or anti-manic drug for another because of poor tolerability will be allowed within 3 months before screening
• Have a CGI-S score of 3 or less at baseline and at screening
• Body mass index (BMI, weight \[kg\]/height \[m2\]) of 18 to 35 kg/m2, inclusive
• Have a supine (after 5 minutes rest) blood pressure between 100 and 140 mmHg systolic, inclusive, and 50 and 90 mmHg diastolic, inclusive
• Apart from the above-mentioned diagnosis, otherwise healthy on the basis of a prestudy physical examination, medical history, 12-lead ECG, and the laboratory results of serum chemistry, hematology, and urinalysis performed within 21 days before the first dose. For renal function tests, the values must be within the normal laboratory reference ranges
• Women must be postmenopausal for at least 2 years, surgically sterile, abstinent, or practicing or agree to practice an effective method of birth control if they are sexually active before entry and throughout the study (effective methods of birth control include intrauterine devices, double-barrier method, and male partner sterilization). Prescription hormonal contraceptives must be used in combination with another method of birth control (e.g., double-barrier method) throughout the study. Women of childbearing potential must have a negative serum pregnancy test result at screening, and a negative urine test at baseline (Day 1).

You may not qualify if:

• Diagnosis of schizoaffective disorder (295.70) according to the DSM-IV
• Meet DSM-IV criteria for rapid cycling
• Acute substance abuse, as evidenced by a positive urine drug screen at screening or baseline (Day 1)
• Positive alcohol test at screening or baseline (Day 1)
• Current suicidal ideation or violent tendencies at the time of screening
• Involuntarily-hospitalized subjects
• Moderate or severe tardive dyskinesia at the time of screening
• History of neuroleptic malignant syndrome
• History of bone marrow depression or acute intermittent porphyria
• History of or a positive result at screening for any of the serology tests (hepatitis B, C, and human immunodeficiency virus \[HIV\])
• History or presence of any relevant cardiovascular (including myocardial infarct or cardiac arrhythmia), respiratory, neurologic (including seizures), renal, hepatic, gastrointestinal (including surgeries, severe gastrointestinal narrowing, and malabsorption problems), endocrine, hematologic, or immunologic disease

Sponsors & Collaborators

• Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: lead

Related Links

• A study of the effect of carbamazepine on the pharmacokinetics of paliperidone extended release (ER) in patients with schizophrenia or bipolar I disorder.

MeSH Terms

Conditions

Schizophrenia; Bipolar Disorder; Mood Disorders

Interventions

Paliperidone Palmitate; Carbamazepine

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Bipolar and Related Disorders

Intervention Hierarchy (Ancestors)

Isoxazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrimidines; Dibenzazepines; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial

  Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: November 20, 2008
• First Posted: May 4, 2009
• Study Start: September 1, 2006
• Study Completion: March 1, 2007
• Last Updated: May 18, 2011

Record last verified: 2010-04